F rontotemporal dementia (FTD) is a highly heritable and common cause of presenile dementia often caused by dominantly acting mutations in the microtubule-associated protein tau (MAPT; tau) and in two other genes, granulin precursor (GRN) and chromosome 9 open reading frame 72 (C9orf72) 1 . Tau pathology is also a core feature of numerous other neurodegenerative syndromes, including Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), and is associated with the pattern of cognitive decline in AD (PSP; for a review see refs [2] [3] [4] ). Thus, identifying the mechanisms by which tau and other dementia-causing mutations lead to neurodegeneration is of foremost importance in developing new therapies for dementia.
F rontotemporal dementia (FTD) is a highly heritable and common cause of presenile dementia often caused by dominantly acting mutations in the microtubule-associated protein tau (MAPT; tau) and in two other genes, granulin precursor (GRN) and chromosome 9 open reading frame 72 (C9orf72) 1 . Tau pathology is also a core feature of numerous other neurodegenerative syndromes, including Alzheimer's disease (AD) and progressive supranuclear palsy (PSP), and is associated with the pattern of cognitive decline in AD (PSP; for a review see refs [2] [3] [4] ). Thus, identifying the mechanisms by which tau and other dementia-causing mutations lead to neurodegeneration is of foremost importance in developing new therapies for dementia.
Translating mechanistic studies in mouse models of dementia to human clinical trials has proved challenging 5, 6 . We reasoned that one contributing factor, aside from the evolutionary distance between mouse and humans 7 , is that common laboratory mouse strains are highly inbred. Although genetic background profoundly affects the biochemical and behavioral repertoires of mouse models of AD 8, 9 , virtually all studies of neurodegeneration in mice rely on a single inbred strain 10, 11 . In this study, we took a multistep systems biology approach to identify robust, human disease-relevant gene networks. To minimize the likelihood that findings were dependent on a single genetic background, we crossed transgenic (Tg) mice harboring the FTD-causing P301S mutation onto three distinct backgrounds and identified early transcriptomic changes observed across mutant F1 progeny, comparing vulnerable regions, such as the cortex and brain stem, to regions less affected in the human tauopathies, such as the cerebellar hemispheres 12 . Through gene network analysis, we identified two major coexpression modules that are conserved across genetic backgrounds and in humans. These modules delineate key pathways deregulated in disease and are differentially enriched for genetic drivers of human FTD, AD and PSP. Using an unbiased integrative genomics approach, we uncovered genome-wide relationships between miRNAs and their biological targets; we experimentally validated these relationships by demonstrating that overexpression of a predicted driver, miR-203, recapitulates the mRNA expression patterns observed with disease and promotes neurodegenerative pathways. As a proof of principle, we also showed that one can leverage these highly conserved coexpression modules to identify tool compounds that mitigate the neurodegeneration induced by miR-203.
Results
We analyzed the F1 offspring resulting from crosses of TPR50 mice expressing the human tau P301S transgene 13 onto FVB, DBA and parent Here, we apply a multistage, systems biology approach to elucidate the disease mechanisms in frontotemporal dementia. We identify two gene coexpression modules that are preserved in mice harboring mutations in MAPT, GRN and other dementia mutations on diverse genetic backgrounds. We bridge the species divide via integration with proteomic and transcriptomic data from the human brain to identify evolutionarily conserved, disease-relevant networks. We find that overexpression of miR-203, a hub of a putative regulatory microRNA (miRNA) module, recapitulates mRNA coexpression patterns associated with disease state and induces neuronal cell death, establishing this miRNA as a regulator of neurodegeneration. Using a database of drug-mediated gene expression changes, we identify small molecules that can normalize the disease-associated modules and validate this experimentally. Our results highlight the utility of an integrative, cross-species network approach to drug discovery.
Identification of evolutionarily conserved gene networks mediating neurodegenerative dementia
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NAtURe MedIcINe C57BL/6 lines (Fig. 1a) . All three F1 crosses share key features of the disease 13, 14 , including decreased survival (Fig. 1b) and body weight ( Supplementary Fig. 1a,b) , progressive accumulation of hyperphosphorylated tau in the cortex and hippocampus (AT8 staining; Fig. 1c) , and prominent astrogliosis and microgliosis ( Fig. 1d-f) . We observed that, consistent with previous reports that FVB mice can be more vulnerable to neurodegeneration, F1 tau P301S Tg mice on the FVB/C57 (TPR50 × FVB/NJ) background had decreased survival and increased pathological tau compared with the C57/C57 (TPR50 × C57BL/6J) and DBA/C57 (TPR50 × DBA/2J) progeny ( Fig. 1b and Supplementary Fig. 1c-h ). Importantly, no significant decrease in the weight of any of the affected brain areas was detected in Tg animals at 6 months ( Supplementary Fig. 1i ), consistent with previous data showing no cell loss at this stage 13 .
We next investigated whether we could identify a robust, diseasespecific transcriptional signature by sampling brain regions varying in disease vulnerability, reasoning that key disease-related gene expression patterns would overlap across affected areas (cortex, hippocampus, brain stem) but would be absent in the cerebellum, which is unaffected 12 . We performed RNA sequencing (RNA-seq) of four brain regions at two time points across the three genetic backgrounds (36 samples per region per time point for a total of Fig. 1 | Experimental design and characterization of TPR50 tau Tg mice in divergent genetic backgrounds. a, Schematic of the experimental design highlighting that TPR50 mice were crossed with three genetically divergent mouse strains and that tissue from the cortex, hippocampus, brain stem and cerebellum from the resulting F1 crosses was isolated at 3 and 6 months for mRNA-seq, miRNA-seq and downstream WGCNA. b, Kaplan-Meier survival curve showing significantly decreased survival of all Tg mice compared to their WT littermates, as well as decreased survival of the FVB/C57-Tg mice compared to DBA/C57-Tg and C57/C57-Tg mice (two-sided log rank test, P = 0.0025; n = 180, 15 males and 15 females per condition). c, Representative images from three independent experiments of phospho-tau-specific AT8 staining and hematoxylin counterstaining in coronal and sagittal brain sections of 3-and 6-month-old Tg mice of all three strains (n = 4 mice per group). Sagittal scale bar, 4 μ m; coronal scale bar, 3 μ m. d, Representative images from three independent experiments showing cortical sections of 6-month-old WT and Tg mice of all three strains stained against Iba1 (red) and GFAP (green) and the nuclear counterstain DAPI (blue). Scale bar, 50 μ m. e,f, Quantification of GFAP-positive (e) and Iba1-positive (f) cells from the cortical slices of 6-month-old mice (unpaired two-tailed t-test; n = 6 images per mouse, 3 mice per genotype). The center line represents the mean, and error bars show s.e.m.
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288 RNA-seq samples; Fig. 1a and Methods). The differentially expressed genes from Tg and wild-type (WT) mice clearly separate the tau mutant from WT genotypes within the affected brain regions ( Supplementary Fig. 2a-c) , but not in the cerebellum ( Supplementary  Fig. 2a) , and are consistent across strains ( Supplementary Fig. 2d,e) . There was significant overlap in differential expression (Methods and Supplementary Fig. 3a) between the cortex and hippocampus, and there was significant correlation between fold changes in differentially expressed genes (Rank-rank hypergeometric test; P = 1.0 × 10 -409
) from these two regions (R 2 = 0.76, slope = 0.92; Supplementary Fig. 3a) . We found lesser, but significant correlation in gene expression between the cortex and brain stem (R 2 = 0.33, slope = 0.82; Supplementary Fig. 3a) . Consistent with the absence of significant cell loss at 6 months in this model 13 , positive regulators of apoptosis (GO:0043065) did not show significant changes across all three strains ( Supplementary Fig. 3b -e) and negative regulators of apoptosis (GO:0043066) showed modest, more significant changes ( Supplementary Fig. 3f-i) . Although we did not observe frank apoptosis, we saw evidence for initial activation of the cellular pathways associated with inflammation in the cerebral cortex by 6 months, including increases in glial fibrillary acidic protein (GFAP) and ionized calcium-binding adapter molecule 1 immunoreactivity in the cortex ( Fig. 1d-f) .
We observed no significant overlap in gene expression between the cortex and cerebellum ( Supplementary Fig. 3j ,k) and no correlation between differentially expressed genes in the cortex and cerebellum (R 2 = 0.01, slope = 0.14; Supplementary Fig. 3a ). Even more striking is that the expression changes of the top upregulated genes in the cerebellum were reversed in the cortex ( Supplementary  Fig. 3l ), implying that protective changes may potentially occur in the cerebellum, as has been previously suggested 12 .
Identification of disease-relevant mRNA modules. To place gene expression changes in a systems-level framework, we performed consensusweighted gene coexpression network analysis (WGCNA 15, 16 ) across all three heterozygous F1 mouse strains to identify relationships not observed in only a single background ( Supplementary Fig. 4a and Supplementary Table 1) . We identified four mRNA modules significantly correlated with the transgenic condition in the cortex, which we initially labeled the salmon, turquoise, magenta and pink modules according to the WGCNA conventions (Bonferroni-corrected P < 0.05; Fig. 2a ). Three of these modules are downregulated (salmon, magenta and pink) and one module is upregulated (turquoise) in Tg mice (Fig. 2a) . Cell-type enrichment analysis demonstrated that the salmon module is enriched in neuronal markers, the magenta module in oligodendrocyte markers and the turquoise module in microglial, astrocyte and endothelial markers (Fig. 2b ) across multiple different cell-type-specific gene expression datasets ( Supplementary Fig. 4b ). Gene ontology analyses are consistent with the cell-type enrichments, showing that the salmon module is enriched for synaptic pathways and magenta for DNA repair and transcription, while the turquoise module is enriched for immune and inflammatory categories ( Supplementary Fig. 4c,d) .
We next calculated the correlation between expression changes and an established early disease marker, the burden of hyperphosphorylated tau, which has been shown to correlate with disease progression in human FTD and AD 17, 18 . Genes that correlated highly with phosphorylated (phospho)-tau levels (R 2 > 0.6; Methods) were found to be significantly enriched in the salmon (42-fold) and turquoise modules (9.5-fold), but not in the magenta and pink modules ( Supplementary Fig. 4e ) we therefore focused our subsequent analysis on the salmon and turquoise modules. Given the consistent cell-type enrichments and strong gene ontology enrichments (Fig.  2b ,d-g and Supplementary Fig. 4b-d) and to provide more intuitive names for these core disease-associated modules, we relabeled the salmon module, the neurodegeneration-associated synaptic (NAS) module, and the turquoise module as the neurodegeneration-associated inflammatory (NAI) module.
To further investigate whether the expression changes were dependent on changes in cell-type composition or reflected cellintrinsic signaling changes, we applied a multivariate linear regression model using the top 100 cell-type-specific marker genes for five major cell types 19, 20 (Methods) . Both modules retained their significant association with the transgenic condition (salmon, r = − 0.73, P = 8.6 × 10
; turquoise, r = 0.71, P = 3 × 10
), indicating that they are independent of changes in cell-type composition caused by neuronal loss or gliosis. Moreover, both the NAI and NAS module eigengenes (MEs) showed changes across the affected brain regions (cortex, Fig. 2e,h; hippocampus, Supplementary Fig. 4f ,g; brain stem, Supplementary Fig. 4h,i) , but not the cerebellum (Fig. 2i,j) , prior to decreases in brain weight that would be indicative of cell loss ( Supplementary Fig. 1i ). This is further supported by analysis of expression profiles from sorted neurons and glia from the Tg4510 and PS2APP AD models, which showed cell-intrinsic changes in the NAI and NAS module trajectories ( Supplementary Fig. 5a-d) . The NAI module was highly preserved in both microglia and astrocytes and significantly upregulated in these populations in Tg mice ( Supplementary Fig. 5a ,c,d-l), while the neuronal NAS module was highly preserved in sorted neurons and downregulated in Tg mice ( Supplementary Fig. 5b ,e-l).
We next used experimentally derived databases of human protein-protein interactions (PPI) from Inweb 21 and BioGRID 22 to create an integrated coexpression-PPI network 23 to functionally annotate network edges and provide independent validation 24 ( Fig.  2c,f) . One of the hubs of the NAS module, STX6, a SNARE protein 25 , is also one of the few known genetic risk factors for tauopathy, having been previously implicated by genome-wide association studies (GWAS) and expression quantitative trait loci analyses in PSP. Other hub proteins, such as Syt4, Nlgn1 and Nrgn, also play important roles in synaptic maintenance and function 26, 27 . Functional annotation of the NAS module with gene ontology and Kyoto Encyclopedia of Genes and Genomes terms confirms its broader relationship to synaptic function ( Fig. 2d and Supplementary Fig. 4c ). In contrast, functional annotation of the NAI module highlights pathways associated with astrogliosis and inflammatory changes 28 , including T cell activation and Toll-like receptor signaling pathways ( Fig. 2g and Supplementary Fig. 4d ). Among the most central hub genes of the NAI module are Tnip1 and Malt1, important inflammatory signaling genes 29 . The integrated coexpression-PPI network derived from the NAI module also contains the gene Fus. Mutations in this gene account for approximately 4% of familial amyotrophic lateral sclerosis (ALS), and it forms aggregates in ALS and FTD 30 .
Reproducibility of disease-specific modules across mouse models and human disease. Further analysis of four independent datasets from mouse models harboring pathological tau mutations, including a replication dataset using the Tg4510 tau model (Methods and Supplementary Fig. 5f ), confirms the preservation of the NAI and NAS modules ( Supplementary Fig. 5e ) and the expected changes in gene expression early in the disease course ( Supplementary  Fig. 5f-h,l) . Comparison of the NAS and NAI modules in mice harboring four different AD and FTD risk mutations (PS2APP, CRND8, APP/PS1 and GRN; see Methods) was also performed to assess to what extent these modules represent convergent pathways across models harboring different pathological proteins. The NAS and NAI models are highly preserved and their disease associations are maintained; both NAI and NAS module expression changes occur with similar temporal profiles across each of these models ( Supplementary Fig. 5e ,i-l).
Considering this cross-mouse model conservation, we next assessed module preservation in human disease models and postmortem tissue samples to validate their human relevance (see The edges between nodes represent both gene coexpression and PPI, permitting us to focus on the hub genes observed at both the RNA and protein level. d, Gene ontology term enrichment of the NAS module using 794 NAS modules genes (permutation test z-score). e, Trajectory of the NAS ME in the cortex of TPR50 mice across different strains (unpaired two-sided Wilcox rank test; n = 6 mice per group). f, Coexpression PPI network plot of the NAI module. The top 30 hub genes are indicated by gene name. g, GO term enrichment of the NAI module using 1,833 NAI module genes. h, Trajectory of the NAI ME in the cortex of TPR50 mice across different strains (unpaired two-sided Wilcox rank test; n = 6 mice per group). i, Trajectory of the NAS module eigengene in the cerebellum of TPR50 mice across different strains (unpaired two-sided Wilcox rank test; n = 6 mice per group). j, Trajectory of the NAI module eigengene in the cerebellum of TPR50 mice across different strains (unpaired two-sided Wilcox rank test; n = 6 mice per group). In the boxplots in e and h-j, the upper and lower lines represent the 75th and 25th percentiles, respectively. The center line represents the median.
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Human FTD, frontal cortex
Protein levels of module genes human FTD Human FTD, cerebellum P = 0.32 NAS ME NAS ME ) and tau-negative FTD (FTD-tau neg.) are shown (unpaired two-sample Wilcoxon rank-sum test). e, log 2 fold change of the top 20 NAS and NAI module genes at the mRNA and protein level. f, NAS and NAI ME in human FTD and control protein samples from the cortex. GRN-positive FTD (FTD GRN pos.) and GRN-negative FTD (FTD GRN neg.) are shown (unpaired two-sample Wilcoxon rank-sum test; control n = 8, GRN-Pos. n = 6, GRN-Neg. n = 10). g-o, NAS and NAI MEs in various neurological diseases: human AD temporal cortex (g, control n = 52, AD n = 52) 44 ; human AD frontal cortex (h, control n = 308, AD n = 157) 36 ; human AD frontal cortex proteomics (i, control n = 15, AD n = 20) 45 ; human pathological aging temporal cortex (j, control n = 70, pathological aging n = 30) 44 ; human ALS frontal cortex (k, control n = 9, C9orf ALS n = 8, Sporadic ALS n = 10) 46 ; human PSP temporal cortex (l, control n = 73, PSP n = 83) 44 ; human major depressive disorder (MDD) (m, control n = 67, MDD n = 66) 47 ; human schizophrenia (n, control n = 167, schizophrenia n = 131) 48 ; and bipolar disorder (o, control n = 65, bipolar disorder n = 40) 48 . Unpaired two-sample Wilcoxon rank-sum test. In all the boxplots, the upper and lower lines represent the 75th and 25th percentiles, respectively. The center line represents the median. p, Mean scaled enrichment of GWAS hits (calculated P value < 0.05) from FTD GWAS 49 , PSP GWAS 50 and AD GWAS 51 in various TPR50 modules (n = 15 modules). NAI module enrichment for AD risk genes was still significant after omitting APOE from the analysis (Supplementary Table 4d ). 
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Methods, Supplementary Table 2a for list and characteristics of  all human datasets, and Supplementary Table 2b ,c). The NAS and NAI modules are dysregulated in the cortex of patients, but not in the cerebellum, both in previously published microarray-based data and in our newly generated RNA-seq dataset (Fig. 3a-d and Supplementary Fig. 5e ,m,n) consisting of both tau-positive and taunegative FTD (Fig. 3c) . Moreover, the NAS module and its diseasetrait relationship are preserved in induced pluripotent stem cell (iPSC)-derived neurons from human FTD patients carrying GRN mutations ( Supplementary Fig. 5e,o) . We also performed mass spectrometry-based, label-free, quantitative proteomics in an independent set of GRN-positive and GRN-negative FTD frontal cortex samples ( Supplementary Fig. 5p , Supplementary Table 2d and Methods). We found similar NAI and NAS expression patterns at the mRNA and protein level (Fig. 3e ) both in GRN-positive and GRN-negative FTD samples, compared with age-matched controls (Fig. 3f) . Taken together, our analyses show that the NAS and NAI coexpression modules are conserved across multiple model systems and generalize from mouse to human, reflecting convergent RNA coexpression and protein-level changes in FTD.
Examination of RNA-seq and proteomic postmortem brain dataset from patients with AD showed preservation of both the NAI and the NAS modules at the mRNA (Fig. 3g,h, Supplementary Fig.  5e and Supplementary Table 4a ) and protein (Fig. 3i) level. Notably, both modules are not dysregulated in cases of pathological aging without dementia (P = 0.77; Fig. 3j ), indicating that they are not related to the presence of Aβ amyloid plaques alone 31 . The NAS and NAI modules are also dysregulated in C9orf72-related and sporadic ALS (Fig. 3k) and PSP (Fig. 3l ), but not in major depression (Fig.  3m) , schizophrenia (Fig. 3n ) or bipolar disorder (Fig. 3o) . These results support the relevance and specificity of these changes to allied human neurodegenerative syndromes, but not other nondegenerative forms of neuropsychiatric disorders.
Assessment of genetic risk within modules. Transcriptomic changes may be the cause or consequence of disease, so integrating these data with genetic risk data provides a means to further understand their relationship to potential causal mechanisms (for example, see refs 32, 33 ). Several AD candidate genes, including APOE, CLU, PICALM, C1q and TREM2 mapped to the NAI module (Fig. 3p , Methods and Supplementary Table 1i); in contrast to AD, FTD and PSP, GWAS data showed significant enrichment in the NAS module, which contains risk genes such as SLC32A1, NSF and ELAVL2 (Fig. 3p) . These differential module enrichments indicate that the genetic risk for AD, FTD and PSP likely operates via distinct causal pathways that may converge on common downstream neuronal and glial-immune processes.
Identification of potential miRNA drivers. Based on the strong co-expression relationships observed in the NAS and NAI modules, we hypothesized potential coregulation by miRNA. We identified two miRNA modules associated with the transgenic condition (Bonferroni-corrected P < 0.05; Fig. 4a and Supplementary Table 3) : the miM12 module, which is anticorrelated, and the miM16 module (Fig. 4b) , which is positively correlated with the transgenic condition in affected regions, but not the cerebellum ( Fig. 4c and Supplementary Fig. 6a-e) . The miM16 ME is strongly anticorrelated with the NAS ME ( Fig. 4d and Supplementary Fig. 6f ), and predicted targets of miR-203, an miM16 hub, are highly enriched (Methods) in the NAS module ( Fig. 4e and Supplementary Fig. 6g,h ). Consistent with its potential regulatory role, miR-203 is robustly upregulated in Tg mice at 6 months in disease-affected areas ( Fig. 4f and Supplementary Fig. 6i-k) and in the frontal cortex in both tau-positive and tau-negative FTD (Fig. 4g,h ). Protein levels of its targets are also significantly decreased in both granulin-positive and granulin-negative FTD (P < 0.005; Fig. 4i ). These data across mouse and humans suggested that miR-203 may be acting as a driver of the NAS neurodegeneration-associated transcriptional program. Supplementary Fig. 9 . h, Schematic representation of experimental design and timeline to overexpress or inhibit miR-203 in C57BL/6 WT or Tg4510 tau transgenic mouse frontal cortex using the AAV2/9 system. i, NAS ME expression in GFP-positive cells overexpressing miR-203 or sc-miRNA at 3 or 6 weeks after AAV injection in C57BL/6 WT mice (unpaired two-sample Wilcoxon rank-sum test; n = 6 per group). j, Expression of genes involved in positive (GO:0043065) and negative (GO:0043066) regulation of apoptosis in GFP-positive cells overexpressing miR-203 or sc-miRNA at 3 and 6 weeks after AAV injection in C57BL/6 WT mice (unpaired two-sample Wilcoxon rank-sum test; n = 6 per group). 
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NAtURe MedIcINe miR-203 regulates the neuronal mRNA module and causes cell death. To test the predicted causal relationship between miR-203 expression and NAS module downregulation, we acutely overexpressed miR-203 (Fig. 5a ) in primary cortical mouse neuronal cultures (Methods and Supplementary Fig. 7a ), observing downregulation of its predicted targets (Fig. 5b) and the NAS module more broadly (Fig. 5c, Supplementary Fig. 7b and Supplementary  Table 4a ). We also observed increased apoptosis (Fig. 5d) , peaking at DIV8 (1.85-fold; Fig. 5e ), concurrent with peak NAS module downregulation. We further experimentally validated several predicted direct targets of miR-203 (Bcl2l2, Dgkb, Mapk10, Vsnl1) by luciferase reporter assays (Fig. 5f ) and western blot (BCL2L2 and VSNL1; Fig. 5g , see Supplementary Fig. 9 for uncropped blots).
To control for potential confounding by supraphysiological overexpression in vitro, we moderately overexpressed miR-203 (approximately twofold; Methods) or a scrambled miRNA control (sc-miRNA) (Fig. 5h) targeting neurons in WT mice in vivo ( Supplementary Fig. 7c-f) . The NAS module is highly preserved ( Supplementary Fig. 7g and Supplementary Table 4a ) and downregulated in neurons overexpressing miR-203 after 6 weeks (Fig. 5i) . Strikingly, the level of miR-203 expression correlates remarkably well with the downregulation of both miR-203 predicted targets (R 2 = 0.81, slope = − 2.3; Supplementary Fig. 7h ) and NAS module genes (R 2 = 0.81, slope = − 2.2; Supplementary Fig. 7i ). Furthermore, apoptotic pathways are altered in miR-203-overexpressing neurons (Fig. 5j and Fig. 9 ), indicating that the decrease in cell death is not a result of changes in viral infection, miRNA processing or regulation of miR-203 by scriptaid. The center line represents the mean, and error bars show s.e.m. d, Representative images from three independent experiments of TUNEL staining in mouse primary cortical neurons overexpressing miR-203 or sc-miRNA (control) at DIV7 treated with DMSO control and 0.5 µ M or 1 µ M SAHA for 24 h prior. Green, GFP; red, TUNEL; blue, Hoechst. Scale bar, 25 mm. e, Quantification of TUNEL positive cells from three independent experiments treated with SAHA (unpaired two-tailed t-test; n = 15 per group). The center line represents the mean and error bars showing s.e.m. f, Trajectory of the NAS ME in cultures infected with either the miR-203-or sc-miRNA-lentiviral construct treated with either DMSO control or 0.5 µ M or 1 µ M SAHA (unpaired two-tailed Wilcox rank test; n = 6 per group). g, Trajectory of the NAS ME in human iPSC-derived neurons from control and A152T Tau patients treated with either DMSO control or 0.5 µ M, 1 µ M or 2.5 µ M SAHA (unpaired two-tailed Wilcox rank test; n = 6 per group). In all the boxplots, the upper and lower lines represent the 75th and 25th percentiles, respectively, while the center line represents the median.
NAtURe MedIcINe (CASP-8) protein expression (Fig. 5k and Supplementary Fig. 7j) . Additionally, miR-203 overexpression in 1-month-old Tg4510 tau transgenic cortex ( Supplementary Fig. 8a,b) causes downregulation of predicted miR-203 targets (Fig. 5l) , the NAS module (Fig. 5m) , genes involved in calcium signaling and neuroactive ligand receptors ( Supplementary Fig. 8e,f) and a significant increase in CASP-8 protein (Fig. 5n ) and apoptotic pathways ( Supplementary Fig. 8c,d) .
To further investigate the causal role of miR-203, we inhibited miR-203 expression in neurons using a 'Tough Decoy' (TuD) adeno-associated virus (AAV) system 34 in vivo in Tg4510 mice (Fig. 5h) . Both short-term (6 weeks; Supplementary Fig. 8g,h ) and longer-term (4 months; Supplementary Fig. 8i,j) inhibition of miR-203 oppose the pathological transcriptional changes in predicted miR-203 targets (Fig. 5o and Supplementary Fig. 8k ) and the NAS module broadly (Fig. 5p and Supplementary Fig. 8l ), including genes involved in calcium signaling and neuroactive ligand receptor pathways ( Supplementary Fig. 8m,n) , and apoptosis ( Fig. 5q and Supplementary Fig. 8o,p) . Reducing miR-203 did not affect phospho-tau immunostaining ( Supplementary Fig. 8q,r) , which is consistent with its acting downstream of tau pathology. Previous work has shown that 5-month-old Tg4510 mice show reduced neocortical network activity based on proto-oncogene c-Fos immunoreactivity 35 . C-Fos intensity was also significantly increased in mutant neurons expressing the miR-203 TuD construct, compared to those expressing the control construct (P < 0.0001; Fig. 5q and Supplementary Fig. 8s ), suggesting functional rescue. These findings demonstrate that inhibition of miR-203 can reverse the expression patterns of both the NAS module and apoptotic pathway genes associated with disease state in vivo, while overexpression of miR-203 promotes downregulation of the NAS module and a neurodegenerative phenotype.
Pharmacological manipulation of NAS module genes.
We reasoned that if the patterns of gene expression robustly associated with disease state across mice and humans represented causal phenomena, as suggested by GWAS enrichment, then their reversal should ameliorate the miR-203-mediated cell death phenotype. To test this, we screened the Connectivity Map (CMAP), a public compendium of cell line gene expression responses to drugs, to identify small molecules predicted to reverse the NAS or NAI module changes observed across pathological conditions, albeit in nonneuronal cells. Four of the top ten hits were histone deacetylase inhibitors (Supplementary  Table 4c ), which was significant (permutated P < 1 × 10
−5
). We chose two of the predicted molecules, scriptaid, which was the top hit in CMAP (enrichment score = − 0.969; Fig. 6a ) and suberanilohydroxamic acid (SAHA) (vorinostat; enrichment score = − 0.846), which is undergoing human clinical trials (NCT03056495). As predicted, adding scriptaid to miR-203-overexpressing neurons decreased the neuronal death caused by miR-203 overexpression to levels equivalent to controls (unpaired t-test; Fig. 6b,c) . We also found that 0.5 μ M SAHA decreased miR-203-induced cell death (Fig. 6d,e) . SAHA upregulated NAS module genes (Fig. 6f) ; however, SAHA showed toxicity at 1 μ M even in control neurons (Fig. 6f) . Next, we treated human iPSC-derived neurons from controls and patients with FTD with SAHA, observing that SAHA upregulates NAS module genes in a dose-dependent manner (Fig. 6g) . Therefore, we conclude that miR-203 directly regulates many NAS module hub genes and that the histone deacetylase inhibitors, scriptaid and SAHA, by targeting the NAS and NAI module genes and normalizing their expression, can ameliorate miR-203-induced proneurodegenerative changes.
Discussion
The mechanisms underlying neurodegenerative diseases are still poorly understood, a factor that impedes the design of therapeutic interventions to treat these disorders. Rather than focusing on a priori candidate genes, we pursued a systematic, genome-wide, functional genomics approach. Such studies have not been realized in the study of most neurodegenerative diseases, with a few notable exceptions [36] [37] [38] . By taking genetic background into consideration, representing diverse causal mutations in transcriptomic network analyses and validation in a dozen independent datasets, we identify disease-relevant gene networks representing specific molecular pathways. It is noteworthy that modules identified in the initial individual F1 crosses that are not conserved and dysregulated across all three strains are also not conserved in other mouse models or the human brain ( Supplementary Fig. 10a-c) , supporting the approach we have taken.
In functional genomic studies, each experimental system on its own, whether in vitro systems, in vivo mouse models or postmortem human tissue, has significant limitations 39 . In this study, we show how a multistage systems biology analysis coupled with substantial in vitro experimental validation provides a framework for discovery of new disease mechanisms and therapeutic targets. We leverage the benefits of animal models of human disease, which permit the temporal assessment of changes before substantial atrophy and cell loss while mitigating the potential bias introduced by a single genetic background. We also consider the principles of regional vulnerability and disease trajectories 12, 40 and find that gene networks associated with transgenic status are altered in brain areas that show signs of neurodegeneration. Conversely, in the cerebellum, a brain region that is spared in AD and FTD, the expression of the NAS and NAI modules, as well as miR-203, does not change significantly.
A key issue in any analysis of gene expression in disease is that changes in gene expression may be either a cause or consequence of the disorder. To advance our work toward identifying causal drivers, we experimentally validate a putative miRNA driver of the altered transcriptional networks, miR-203, which has previously not been implicated in neurodegeneration, and we show reversal by gene-network-predicted pharmacological regulators. We also find significant enrichment of common genetic risk for both FTD and PSP in the neuronal NAS module and enrichment for AD GWAS signals in the NAI module, which is enriched in glial and immune genes. These data further support the potential causal role of these modules and suggest different causal pathways in AD versus FTD and PSP, the latter of which are considered primary tauopathies 3, 4 It is important to note that both expression changes in the disease-associated gene modules NAS and NAI, as well as the upregulation of miR-203, though clearly a point of convergence, are most likely downstream of initial pathological insults, whether caused by tau or other major risk genes. From this perspective, these modules represent robust, highly conserved biological processes that provide a crucial link in the chain between an initial causal genetic insult and neuronal death and inflammation. As we show, longterm inhibition of miR-203 in the Tg4510 model, while upregulating antiapoptotic pathways, downregulating proapoptotic pathways and increasing neuronal activity as measured by c-Fos activation, does not reduce the phospho-tau burden ( Supplementary Fig. 8q,r) . Though pharmacologically targeting these gene networks, or miR-203 itself, may not reverse tau aggregation or Aβ plaque formation, it may provide a means to uncouple dysfunction of aggregationprone proteins from inflammation, neurodegeneration and their behavioral outcome-dementia. Supporting this possibility is the fact that neither the NAS nor the NAI modules are dysregulated in patients that show pathological aging, in which significant amyloid plaque density, but no dementia, is observed. Therefore, developing therapies that reverse the changes in the disease-associated gene coexpression modules may be an opportunity to impede neurodegeneration across a broad spectrum of dementias without having to target unique upstream pathological events. Moreover, we hypothesize that regulators of these highly conserved transcriptional programs, such as miR-203, may be new therapeutic targets.
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Efforts to target miRNAs to treat diseases are already underway 41 and traditional antisense oligo-based targets have reached clinical trials 42 , while small-molecule modulators represent a new frontier in miRNA-based therapeutics 43 . In this regard, identifying regulators of the NAI module is also likely to be a fertile avenue for future studies aimed at therapeutic development 44 .
URLs. miRbase, http://www.mirbase.org/; TargetScan database, http://www.targetscan.org/vert_72/; CMP database, https://portals. broadinstitute.org/cmap/.
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NAtURe MedIcINe Methods Animals. TPR50 mice were generated in the C57BL/6J background and maintained at the Shonan Research Center, Fujisawa City, Japan as described previously 13 . TPR50 mice overexpress the tau P301S (4R2N isoform) under the control of a mouse prion promoter. Mice were outbred to DBA/2J and FVB/ NJ strains. Heterozygous F1 male mice (at 3 and 6 months of age) were used to collect brain tissues (cortex, hippocampus, brain stem and cerebellum) for immunohistochemical staining and RNA isolation. WT littermates of the same genetic background and age were used as controls. All procedures involving animals were performed in accordance with the University of California, Los Angeles animal research committee, the National Institutes of Health (NIH) Guide for the Care and Use of Laboratory Animals and by the Experimental Animal Care and Use Committee of Takeda Pharmaceutical Company Limited, Japan. WT C57BL/6J mice were directly purchased from Jackson Laboratories.
Human postmortem brain samples. Postmortem brain tissue from human FTD and control individuals used for mRNA (mRNA-seq) and miRNA sequencing (miRNA-seq) were acquired from the Emory Alzheimer's Disease Research Center brain bank at Emory University School of Medicine. Human postmortem tissues were acquired under Emory University Institutional Review Board with consent from family members. Sample acquisition protocols approved by the University of California, Los Angeles Institutional Review Board were followed, and samples were deidentified before acquisition. Brain sample information and individuallevel metadata are available in Supplementary Table 2b . Proteomics samples were obtained from Penn Alzheimer's Disease Research Center as part of the Accelerating Medicine Partnership for Alzheimer's Disease; sample-level metadata are available in Supplementary Table 2c .
Immunohistochemistry/immunofluorescence. Paraffin-embedded mouse brain samples were briefly deparaffinized and blocked in 5% serum. Sections were stained overnight with phospho-tau (Ser202, Thr205) AT8 clone (Thermo Fisher Scientific) at 1:250 dilution followed by incubation in biotinylated secondary antibody and imaged under microscope. For immunofluorescence, sections were stained with an antibody raised against GFAP (Dako; 1:500) or Iba-1 (Wako; 1:500) followed by incubation in Alexa Fluor 488 or 594 secondary antibody (Invitrogen; 1:500) for 1 h at room temperature and counterstained with DAPI. Images were obtained either with a ZEISS Axio Imager or on a digital slide scanner NanoZoomer 2.0-HT (Hamamatsu Photonics K.K.).
mRNA-seq and miRNA-seq. A quantity of 1 μ g total RNA was used for mRNAseq and miRNA-seq. For mRNA-seq, polyA-selected mRNAs were processed for unstranded libraries using the TruSeq V2 kit (Illumina) that underwent 50-bp paired-end sequencing on an Illumina HiSeq 2500 system. Paired-end reads were mapped to the reference mouse NCBIM37 genome using TopHat2 and Ensembl release 67 annotations (May 2012 data freeze). Count-level data were quantified using union gene models with HTSeq-counts. For miRNA-seq, a second sample from the same total RNA fraction was used, and libraries were prepared using the TruSeq Small RNA Library Prep Kit (Illumina). The 50-bp single-end reads were processed for miRNA expression using the miRDeep2 analysis pipeline.
Coexpression network analysis. Coexpression network analysis was performed in R using the WGCNA package 16 . To identify mRNA modules that are conserved across various Tg mouse strains, we used a consensus network analysis (WGCNA) approach. To identify common expression patterns across genetic backgrounds, we created a signed consensus network for each brain region individually by calculating component-wise minimum values for topological overlap across different mouse strains. For miRNA data, we performed WGCNA analysis using signed networks.
Mouse embryonic cortical cell culture. Cortical tissue from day 15 (E15) C57BL/6J embryos was collected, dissected and washed in ice-cold Hank's balanced salt solution (HBSS; Invitrogen). Tissue was incubated in 0.25% trypsin (Invitrogen) in the presence of DNase I (Roche) at 37 °C for 10 min. Tissue was washed with cold HBSS and titurated in plating media (Gibco Neurobasal Medium; Thermo Fisher Scientific), 20% heat-inactivated horse serum (Thermo Fisher Scientific), 25 mM sucrose and 0.25% Gibco GlutaMAX (Thermo Fisher Scientific) in the presence of DNase I. Dissociated cells were centrifuged at 125g for 5 min at 4 °C, resuspended in plating medium, counted and plated in poly-llysine-coated (Sigma-Aldrich) plates at a density of 300,000 cells ml Stereotactic injection of AAV2/9 into mouse brain. Mice were anesthetized with isoflurane and head-fixed over a heating pad set to 37 °C. Craniotomy was performed according to approved procedures (animal protocol number 2000-159). The eyes were covered with artificial teardrops, the scalp was bisected and the exposed area was sterilized on a stereotactic frame (Model 900 Small Animal Stereotaxic Instrument; David Kopf Instruments). The skull was thinned using a Dremel drill, and 1 μ l of AAV 2/9 (1 × 10 13 vector genomes ml −1 of hSyn-miR203-hSyn-enhanced green fluorescent protein (eGFP); 1 × 10 13 vector genomes ml
of hSyn-scrambled:miRNA-hSyn-eGFP (SignaGen Laboratories)) was injected bilaterally into the frontal cortex (anterior/posterior: + 2.1 mm; mediolateral: ± 1.5 mm; dorsal/ventral: − 2.5 mm) at a rate of 100 nl min −1 using a Hamilton 5-μ l syringe (Hamilton Company). Before each injection, the pipette was lowered 0.1 mm beyond the intended target depth and held in place for 3 min to create space for the injected solution; after each injection, the pipette was held in place for 7 min before retraction to prevent leakage. The incision was sterilized and glued, and postoperative antibiotics (amoxicillin, 50 mg ml −1 ) were administered for 7 d following surgery.
Sample collection and RNA isolation. TPR50 mice at 3 and 6 months of age were killed using cervical dislocation. The cortex, hippocampus, brain stem and cerebellum were dissected on ice-cold PBS buffer solution and flash-frozen to minimize RNA degradation. RNA was isolated from different brain regions of interest from each sample using the miRNeasy kit with on column DNase digestion (QIAGEN) using a QIAcube automated system. For each RNA sample, the RNA concentration was determined using a Quant-iT RiboGreen RNA Assay Kit (Invitrogen), and RNA integrity was quantified using the RNA integrity number (RIN) 52 on an Agilent 2200 TapeStation. Frozen human brain samples obtained from Emory brain bank were dissected on dry ice in a dehydrated dissection chamber to reduce degradation effects from sample thawing or humidity; 50-100 mg tissue samples were used to isolate RNA using the miRNeasy kit with on column DNase digestion; samples with RIN > 2 were used further.
Mouse primary cortical neurons were washed with ice-cold RNase-free PBS; QIAzol lysis reagent (QIAGEN) was immediately added to the 6-well plates. RNA was isolated using the miRNeasy kit according to the manufacture's protocol.
Several datasets have been used throughout the study, details of which can be found in Supplemental Enzyme-linked immunosorbent assay. Total tau and pT231 tau content were measured by commercial tau ELISA kits according to the manufacturer's instructions (total tau, KHB0041; pT231 tau, KHB8051; Invitrogen). Briefly, standards, radioimmunoprecipitation assay-soluble or sarkosyl-insoluble samples were applied to the ELISA plate. After washing, a biotin-conjugated detection antibody was applied. The positive reaction was enhanced with streptavidinhorseradish peroxidase and colored by 3,3′ ,5,5′ -tetramethylbenzidine. The absorbance at 450 nm was then measured, and the concentration of tau protein was calculated from the standard curve.
RNA-seq library preparation. For the TPR50 mouse data, 1 μ g of total RNA was used to obtain poly(A)-selected mRNAs, which were processed for unstranded libraries using the TruSeq RNA Sample Prep v2 kit (Illumina). Briefly, the poly(A) tail-containing mRNA was isolated using oligo-dT-attached magnetic beads; mRNA was fragmented and first-strand complementary DNA (cDNA) was generated using SuperScript II Reverse Transcriptase (Invitrogen) followed by second-strand cDNA generation. Barcodes and adapters were added and subsequent steps followed the TruSeq protocol to generate fragment sizes (150-500 bp; mean, 250 bp). The libraries were quantified with the Quant-iT PicoGreen assay (Thermo Fisher Scientific) and validated on an Agilent 2200 TapeStation system. Libraries were multiplexed with 24 samples per lane, and each lane was sequenced several times to get an average read depth of 40-50 million reads per sample on an Illumina HiSeq 2500 instrument using a high-output mode with standard chemistry and protocols for 50-bp paired-end reads.
For postmortem human data, 1 μ g of total RNA was used for ribosomal RNA (rRNA) depletion with the Ribo-Zero Gold Kit (Illumina). Remaining RNA was size-selected using AMPure XP beads (Beckman Coulter), and standard libraries were prepared following Illumina's TruSeq protocols for 50-bp paired-end reads. Libraries were sequenced at an average read depth of 60-70 million reads per sample on a HiSeq 2500 instrument using rapid mode.
We used a SMART-Seq v4 Ultra Low Input RNA Kit (Clontech) for the library preparation of fluorescence-activated cell sorting (FACS)-sorted adult mouse neurons. RNA from FACS-sorted cells (~1,000 cells) were isolated with the NucleoSpin RNA XS kit (Clontech) with on column DNase digestion according to the manufacturer's protocol; the RNA was eluted in 10 μ l of RNase-free water. rRNA was depleted from the eluted total RNA, and cDNA was synthesized using PrimeScript Reverse transcriptase (Clontech). Sequencing adapters were added, and the library was amplified using SeqAmp DNA Polymerase (Clontech). Strand-specific library was size-selected using AMPure XP beads and validated for fragment sizes (200-1000 bp, peaking at 300 bp). Libraries were multiplexed with 12 samples per lane, and each library was sequenced several times to get an average . FACS-sorted neuronal RNA-seq data were processed similarly to the human RNA-seq data except that the paired-end reads were mapped to the reference mouse NCBIM37 genome with Ensembl release 67 annotations using the RNA-STAR aligner (version 2.4.2a).
miRNA-seq read alignment and processing. Mouse and human miRNA-seq read alignments and quantifications were performed using the miRDeep2 package 66 . We used the mapper.pl script to map the 50-bp single-end reads to the reference genome, NCBIM37 for mouse and GRCh37 for human. We then used the quantifier.pl script of the package to map the reads to annotated miRNAs, which were downloaded from the miRBase (version 20 for mouse data and miRbase version 21 for human data) website (see URLs). The script gives a count-level quantification of each known miRNA; we used the quantile-normalized values as provided by the script for downstream analyses.
Microarray: mouse embryonic cortical cells. Total RNA isolated from E15 cortical cultures using the miRNeasy Mini Kit (QIAGEN) were processed on a mouse Ref8 v2 BeadChip microarray (Illumina) according to the manufacturer's protocol. Microarray data analysis was performed with the R and Bioconductor packages. Raw expression data were log 2 -transformed and normalized by quantile normalization. Probes were considered robustly expressed if the detection P value was 0.05 for at least half of the samples in the dataset. Probes were remapped to mouse Ensembl gene IDs (version 67; May 2012 data freeze) for comparison with RNA-seq data.
Differential gene expression.
We used principal component analysis (PCA) of the normalized gene expression data to understand the biological and technical covariates effecting the data. For the TPR50 dataset, we found that none of the first five gene expression PCAs correlated significantly with the batch or sequencing PCAs. Thus, we only performed differential expression within a brain region and separately for each age group using the normalized FPKM values in the linear regression model in R as follows:
lm (expression Transgenic Condition MouseStrain Sequencing Lane Batch RIN)
For all other mouse datasets, RIN, the first two sequencing PCAs, batch and experimental batch were used as the covariates in the linear regression model. For the human data, additional traits like age, sex and postmortem interval (PMI) were also used for the analysis. We also performed differential gene expression for the TPR50 dataset using the DESeq2 R package 67 using raw counts data from HTSeqcounts following the default parameters and taking transgenic condition, mouse strain, sequencing lane batch and RIN as covariates for the DESeq2 regression.
mRNA-weighted coexpression network analysis. Coexpression network analysis was performed using a user-friendly R WGCNA library 16 . We wanted to investigate mouse brain coexpression networks that are disease-specific but are independent of genetic backgrounds (C57BL6/J, DBA and FVB). Thus, we used a consensus network analysis approach, which provided us with groups of coexpressed genes (or modules) that are not affected by mouse genetic background. TPR50 mice were generated using a bacterial artificial chromosome clone as the transgene, which overexpressed P301S mutation in the human MAPT gene (4R2N isoform). However, the bacterial artificial chromosome clone had three additional confounding genes, Prnd, Erv3 and Rassf2 in the construct, which were also overexpressed. To remove the effect of the confounding genes, we took the first principal component of the expression of the confounding genes and removed the genes, which are significantly correlated at a false discovery rate (FDR) of P < 0.05. This resulted in the removal of about 1,000 genes, which are highly correlated with the confounding genes. We only used the 6-month time point to construct the initial network. The resulting expression data for each brain region, except for the cerebellum, at the 6-month time point was used to create the consensus network separately; the 'matchLabels' function of the WGCNA package was used to have consistent network labeling between brain regions.
In short, biweighted midcorrelations were calculated for all pairs of genes, and then a signed similarity matrix was created. In the signed network, the similarity between genes reflects the sign of the correlation of their expression profiles. The signed similarity matrix was then raised to the power β to emphasize strong correlations and reduce the emphasis of weak correlations on an exponential scale. The resulting adjacency matrix was then transformed into a topological overlap matrix as described here 68 . Since we are primarily interested in finding coexpression patterns conserved across different mouse genetic backgrounds, we created a consensus network to identify common coexpression patterns across strains, following published methods 69 . After scaling for each individual network (consensus scaling quantile = 0.2), a threshold power of 12 was chosen (because it was the smallest threshold that resulted in a scale-free R 2 fit of 0.8) and the consensus network was created by calculating the component-wise minimum values for topological overlap. Using 1 − TO (dissTOM) as the distance measure, genes were hierarchically clustered. Initial module assignments were determined using a dynamic tree-cutting algorithm (cutreeHybrid, using the default parameters except deepSplit = 4, cutHeight = 0.999, minModuleSize = 100, dthresh = 0.1 and pamStage = FALSE).
The resulting modules or groups of coexpressed genes were used to calculate the MEs or the first principal component of the module. Modules were annotated with the GO-Elite package 70 . We performed module preservation analysis using mRNA module definitions. MEs were correlated with different biological and technical traits like transgenic condition, strain and RIN to find disease-specific modules. Module hubs were defined by calculating module membership (kME) values, which are the Pearson correlations between each gene and each ME. Genes with a kME < 0.7 were removed from the module. Network visualization was done with the igraph package in R 71 . Module definitions from the network analysis were used to create synthetic eigengenes for the 3-month time point and were used to understand the trajectory of various modules across time points. For the cerebellum, a data synthetic ME was calculated using cortex coexpression definitions and plotted.
Cell-type-specific regression analysis. To ensure that the changes in module expression identified were not solely a product of neurodegeneration and gliosis, we employed a multivariate linear regression model to regress gene expression levels against transgenic condition and the first principal component (PC1) of the top 100 cell-type-specific marker genes 72 for five major cell types: neurons; astrocytes; oligodendrocytes; microglia; and endothelial cells. This method removes the confounding effect of changes in cell composition (for example, see refs 19, 20 Module preservation analysis. We used module preservation analysis to validate coexpression in independent mouse and human datasets. Module definitions from the TPR50 consensus network analysis were used as reference and the analysis was used to calculate the z-summary statistic for each module. This measure combines module density and intramodular connectivity metrics to give a composite statistic where z > 2 suggests modest preservation and z > 10 suggests high preservation 73 .
Enrichment analyses for gene sets. Gene set enrichment analysis was performed using a two-tailed Fisher's exact test with 95% confidence intervals calculated FACS sorting of adult mouse neurons. Cortical cell suspensions from adult mouse neurons were labeled with live cell marker DRAQ5 (1 μ l per 1 ml of cell suspension; Thermo Fisher Scientific) and dead cell marker NucBlue (2 drops ml 
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